COLLAGEN SPONGE FOR WOUND CARE

Participate in the extracellular matrix reconstitution and in the soft tissue rebuilding.

CELLIS® Wound facilitates the acceleration of:
• the building of new granulation tissue
• the epithelization process

Biocompatible
• 100% collagen: regeneration of granulation tissue and acceleration of epithelization

Easy application
• Flexibility
• Can be cut to the size and the shape needed

www.meccellis.com
MAKING SAFE TECHNOLOGIES AVAILABLE
**Clinical INDICATIONS**

- Non-infected wounds with healing difficulties
- Wounds with secondary wound healing in the granulation phase
- Wounds in the epithelization phase (e.g. leg ulcer, decubitus ulcer, split skin, burns, secondary healing wounds…)

**Clinical BENEFITS**

- Produces a capillary suction effect and absorbs the discharge from the wound
- Accelerates the regeneration of granulation tissue and the epithelization process

---

### Available sizes

<table>
<thead>
<tr>
<th>sizes</th>
<th>content</th>
<th>product code</th>
<th>shape</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 x 5 cm</td>
<td>3 units per box</td>
<td>CW55</td>
<td></td>
</tr>
<tr>
<td>5 x 10 cm</td>
<td>3 units per box</td>
<td>CW510</td>
<td></td>
</tr>
<tr>
<td>10 x 10 cm</td>
<td>3 units per box</td>
<td>CW1010</td>
<td></td>
</tr>
</tbody>
</table>

---

**Clinical INFLAMMATORY PHASE**

Exogenous collagen influences the epithelialization phase leading to significant acceleration of the epithelialization process.

**INJURY**

**REPAIR PHASE**

Once debridging is achieved, a new extracellular matrix is built. With CELLIS® Wound, the released nature collagen accelerates regeneration of granulation tissue.

**REEPITHELIALIZATION PHASE**

Native collagen released

**GRANULATION PHASE**

Fibroblast cells

**HEALING PHASE**

Macrophages

**INJURY**

Platelets

---

**Clinical BENEFITS**

- Produces a capillary suction effect and absorbs the discharge from the wound
- Accelerates the regeneration of granulation tissue and the epithelization process

---

**TOMORROW’S OPERATIONS TODAY**

Meccellis® Biotech focuses all its know-how in support of surgery.

---

**Class 3 medical device - 0499**

Version July 2014

---

**Distributed by**

**Head office**

Creatio® TECH - 40, rue Chef de Baie - Bâtiment 3
17 000 LA ROCHELLE - FRANCE
Ph: +33 (0)6 58 43 03 87 / +33 (0)7 61 31 11 33
contact@meccellis.com
www.meccellis.com

---

**Brochure is intended for healthcare professionals only.**

The « Instructions for Use » attached to the packaging of each Cellis® Wound product should be read carefully.
Clinical INICATIONS

The biological implant CELLIS® is indicated for the soft tissue repair in complex abdominal wall surgery for which synthetic implants are not adapted (peristomial hernia, incisional hernia, skin defect, ostomy closure...).

Inert, non immunogenic and perfectly biocompatible, the CELLIS® implant can be used for patients with a risk of septic environment.

Examples of CLINICAL CASES

Case 1
This is the case of an incisional hernia with skin necrosis, occlusion of the small intestine and skin defect. A CELLIS® implant of 20 x 30 cm is positioned into the intra-abdomen to reinforce the abdominal wall.

Case 2
This is a definitive colostomy. The CELLIS® Stoma implant of 10 x 10 cm was implanted. Prophylactic use of CELLIS® Stoma can also be recommended for stoma closure to prevent potential herniation.

Case 3
This is the case of an obese patient who had a hiatal hernia due to a too wide distance between the pillars of the diaphragm for normal closure. A CELLIS® Hiatus implant of 10 x 10 cm was used.
CLOSER TO SURGEONS

Meccellis® Biotech is a company selling biological implants made with acellular dermis. Born from the aspiration to better serve surgeons and patients and to correspond to their daily needs.

Our biological implants CELLIS® are the results of a tissue and cellular engineering and continuous dialogue with surgeons.

The constant awareness of the medical world is the foundation of our values, it guarantees the quality of our products.

Making high technologies accessible is at the heart of our concerns

Through the collaboration with scientific committees and surgical teams that trust us, we identify unmet clinical needs and offer the adapted solution by type of surgery.

Our product range CELLIS® will soon be available for new clinical indications.

Our signature carries our ambition:

MAKING SAFE TECHNOLOGIES AVAILABLE

TOMORROW’S OPERATIONS TODAY

Meccellis® Biotech focuses all its know-how in support of surgery.